Related Experiment Video
Updated: Nov 30, 2025

Visualizing Leukocyte Rolling and Adhesion in Angiotensin II-Infused Mice: Techniques and Pitfalls
Published on: January 4, 2018
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from
R Vinci1, D Pedicino2, F Andreotti3
1Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.
Insights
The novel coronavirus disease (COVID-19) is characterized by angiotensin-converting enzyme 2 disruption and thromboinflammatory microangiopathy. This can lead to widespread microvascular plugging, ischemia, and organ failure, representing a potentially fatal vascular disease.
Area of Science:
- Pathology
- Virology
- Cardiovascular Science
Background:
- Clinical, autopsy, experimental, and molecular data on COVID-19 are reviewed.
- Distinctive features of COVID-19 include angiotensin-converting enzyme 2 (ACE2) disruption and thromboinflammatory microangiopathy.
Purpose of the Study:
- To review and consolidate current data on COVID-19.
- To highlight the role of thromboinflammatory microangiopathy in COVID-19 pathogenesis.
Main Methods:
- Review of existing clinical, autopsy, experimental, and molecular data related to COVID-19.
Main Results:
- Viral entry into microvessels disrupts the renin-angiotensin system and causes endothelial injury.
- Activation of the complement cascade and release of von Willebrand factor induce thromboinflammatory reactions.
- Widespread microvascular plugging can result in ischemia and organ failure.
Conclusions:
- COVID-19 data support a paradigm of potentially fatal thromboinflammatory microvascular disease.
- Thromboinflammatory microangiopathy is a critical, under-recognized aspect of severe COVID-19.
Abstract:
We concisely review clinical, autopsy, experimental and molecular data of 2019 coronavirus disease (COVID-19). Angiotensin-converting enzyme 2 disruption and thromboinflammatory microangiopathy emerge as distinctive features. Briefly, entry of the virus into microvessels can profoundly disrupt the local renin-angiotensin system, cause endothelial injury, activate the complement cascade and induce powerful thromboinflammatory reactions, involving, in particular, von Willebrand factor, that, if widespread, may lead to microvascular plugging, ischemia and, ultimately, organ failure. We believe the current COVID-19 data consolidate a widely unrecognised paradigm of potentially fatal thromboinflammatory microvascular disease.
More Related Videos
07:56Monitoring Changes in Human Umbilical Vein Endothelial Cells upon Viral Infection Using Impedance-Based Real-Time Cell Analysis
Published on: May 5, 2023
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Acute Kidney Injury II: Pathophysiology
Hypertension II: Pathophysiology
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Myocarditis I: Introduction